

Index

- abciximab, 191
- adenosine diphosphate (ADP)
 - inhibitors, 190
- adrenocorticotropin hormone,
 - central to peripheral ratio, 141
- Alberta Stroke Program Early CT Score (ASPECTS), 69
- albuterol, 194
- allergy, 163–164
 - anaphylactic reaction, 161
 - contrast media, 163, 193–195
 - heparin, 164
 - local anesthetic reactions, 181
- alteplase, 191
- analgesia, 180–181
- anaphylactic reaction, 161
- anesthetics, 154
 - local, 181
- aneurysms. *See* intracranial aneurysms
- angioplasty. *See* intracranial angioplasty; carotid angioplasty and stenting (CAS)
- anticoagulants, 184–190
 - cessation following intra-arterial stroke treatment, 70–71
 - oral agents, 184–187
 - parenteral agents, 187–190
- anticonvulsants, 182–184
- antihypertensive medications, 155
- antiplatelet agents, 190–191
- antithrombotics, 184–187
 - intra-arterial stroke treatment, 67
 - intracranial aneurysm treatment, 12–13, 21
- aorta, abdominal, translumbar access, 8
- aortobifemoral bypass graft, 2
 - access complications, 2
- apixaban, 184
- argatroban, 187
- arrhythmias, 156–157
- arterial dissection
 - external carotid artery, 125
 - femoral artery, 2–3
 - innominate artery, 114
 - intracranial angioplasty and, 60–61
 - stroke intra-arterial treatment and, 72–74
 - vertebral artery, 110
- arteriovenous fistula (AVF), 6
 - case study, 45
 - dural AVF, 45
 - recurrence, 56
 - spinal cord (SCAVF), 46–47
 - treatment principles, 45
- arteriovenous malformations (AVMs)
 - intracranial, 44–45
 - post-embolization complications, 55–56
 - AVM recurrence, 56
 - intracerebral hemorrhage (ICH), 55–56
 - spinal cord (SCAVM), 47–48
- technical complications, 78–82
 - arterial feeder related complications, 49
 - arterial obliteration without nidus obliteration, 21–22
 - case study, 50
 - distant venous embolization, 55
 - inadequate obliteration of AVM nivos, 54–55
 - inadequate obliteration of pre-nidal aneurysm, 49–53
 - invisible artery appearance, 51–52
 - microcatheter adhesion within embolic material, 52–53
 - microcatheter rupture, 53
 - reflux into feeding pedicle and parent artery, 49–50
 - venous drainage channel obliteration with or without nidus obliteration, 55
 - treatment principles, 44–45
- aspiration of gastric contents, 152
- aspirin, 190
- axillary artery access, 7
- balloon remodeling technique,
 - wide neck intracranial aneurysms, 25–26
- balloon test occlusion (BTO), 132–135
 - classical approach, 133–146
 - complications, 134–135
 - false and incomplete tests, 133–134
- benzodiazepines, 182, 196
- bivalirudin, 188
- blood pressure monitoring, 149
- brachial artery access, 7
- bradycardia, 156
- brain code protocol, 158
- brain death, 158
- bronchospasm, 194
- calcium channel blockers, 192–193
- cardiac monitoring, 149
- cardiovascular complications, 153–157
 - arrhythmias, 156–157
 - hypertension, 153–155
 - hypotension, 156
 - local anesthetic effects, 181
- carotid angioplasty and stenting (CAS), 84
 - adverse hemodynamic event management, 96–97
 - approaching and crossing the lesion, 91–94
 - difficulty crossing distal embolic protection device, 93–94
 - high grade and irregular stenosis, 92–93
- basic technique, 84–88

Index

- carotid angioplasty and stenting (CAS) (cont.)
 - cerebral hyperperfusion syndrome, 101
 - distal embolic protection device retrieval, 95–96
 - device overload with embolic debris, 96
 - difficulty, 95–96
 - extension wires, 98
 - extracranial carotid pseudoaneurysms, 101
 - guide catheter instability, 97
 - perforation of external carotid artery branches, 97
 - stent deployment, 94
 - difficulty with stent delivery system removal, 94–95
 - thromboembolic complications, 98–101
 - trapping of a wire by the stent, 97
 - unexpected thrombus/foreign body management, 98
 - vascular access, 89
 - aorto-iliac occlusion, 90
 - distal CCA stenosis, 89
 - ECA occlusion, 89
 - with unfavorable aortic arch, 89
 - vs carotid endarterectomy (CEA), 104
- carotid endarterectomy (CEA), 84
 - vs carotid angioplasty and stenting (CAS), 104
- cerebral arteriovenous malformations. *See* arteriovenous malformations (AVMs)
- cerebral hyperperfusion syndrome (CHS), 101
- cervical anastomosis, 118
- clopidogrel, 190
- coagulopathy complications, 159–161. *See also* thromboembolic complications
- Cobb's syndrome, 47
- coils, 48. *See also* primary coil embolization
- conscious sedation failure, 153–154
- contrast media
 - allergy, 163, 193–195
 - properties, 167–168
- contrast-induced nephropathy (CIN), 166–178
 - clinical course, 172
 - clinical evaluation, 171
 - definition, 166
 - gadolinium-based contrast agents, 176
 - incidence, 167
 - iodinated contrast media, 166–172
 - pathogenesis, 170
 - preventive strategies, 172–175
 - hemodialysis and hemofiltration, 174
 - hydration, 173
 - N-acetylcysteine (NAC), 174
 - risk assessment, 169
 - risk factors, 169
- corticotropin releasing hormone (CRH), 141
- cranial nerve blood supply, 116
- cranial nerve palsies, 116
- Cushing's syndrome, 135, 137. *See also* inferior petrosal sinus sampling
- cianoacrylates, 48
- dabigatran, 185
- dalteparin, 190
- desmopressin, 142
- dobutamine, 197
- dopamine, 197
- embolic agents, 48–49
 - coils, 48
 - liquid, 28, 48
 - solid, 48
- enoxaparin, 189
- epinephrine, 194, 197
- epitibatide, 191
- erythema, 194
- external carotid artery (ECA)
 - arterial dissection, 125
 - arterial rupture, 125
 - arterial spasm, 118
 - embolization. *See* head and neck embolization
 - occlusion, 89
- extracranial–intracranial anastomotic pathways, 118–119
- cervical anastomosis, 118–124
- orbital region anastomosis, 119–124
- petrous-cavernous region anastomosis, 119
- femoral artery access, 1–2
- femoral artery dissection, 2–3
- fentanyl, 180
- flow diverters, wide neck
 - intracranial aneurysms, 28–31
 - complications, 30
 - deployment in collapsed form, 29
 - difficulty in release of distal end, 29
 - loss of distal access, 30
 - misalignment of deployed system, 29
- flumazenil, 183
- fluoroscopy system, 205–207
- fondaparinux, 188
- fosphenytoin, 183
- gadolinium-based contrast agents (GBCAs)
 - nephrogenic systemic fibrosis relationship, 176–178
 - nephropathy, 176
 - properties, 176
- gastric contents aspiration, 152
- glycoprotein IIb/IIIa inhibitors, 191
- groin complications
 - alternative access routes, 7–8
 - following percutaneous access, 2–8
 - acute lower extremity ischemia, 4–7
 - arterial pseudoaneurysm at access site, 4–5
 - arteriovenous fistula formation, 4–6
 - femoral arterial dissection, 2–3
 - hematoma, 3–4
 - vascular closure device related complications, 5–6
- risk factors for access site complications, 1–2
- aortobifemoral bypass graft access, 2

Index

- pulseless femoral region
 - access, 1–2
- Guglielmi detachable coil (GDC), 13
- head and neck embolization
 - complications, 116–118, 123–127
 - arterial dissection and thrombosis, 125
 - arterial rupture, 125
 - arterial spasm, 118
 - distal vasculature ischemic injury, 126
 - inadvertent embolization of extracranial arteries, 126
 - inadvertent embolization of intracranial arteries, 126
 - direct tumor puncture, 119
 - indications, 116
 - standard vascular access, 119–121
- head and neck trauma, 121–123
 - trauma dissection, 123–124
 - flow restoration, 123
 - large vessel occlusion, 123
 - trauma hemorrhage, 121–123
 - flow restoration, 123
 - large vessel occlusion, 122
 - small vessel occlusion, 121
- hematoma, groin access
 - complications, 3–4
- hemodialysis, contrast-induced nephropathy
 - prevention, 174
- hemofiltration, contrast-induced nephropathy
 - prevention, 174
- heparin, 189
 - allergy, 164
 - intra-arterial stroke
 - treatment, 67
 - thrombosis prevention, 8, 21
- high-osmolality contrast media (HOCM), 167
- hives, 194
- hypertension, 153–155
- hypoglycemia, 194
- hypotension, 156, 194
- hypotension challenge, 133
- hypoventilation, 152
- hypoxemia, 152
- inferior petrosal sinus
 - sampling, 135, 137–139
- central to peripheral
 - adrenocorticotropin hormone ratio, 141
- complications, 145
- corticotropin releasing hormone (CRH), 141
- desmopressin, 142
- false negative results, 142
- false positive results, 142
- intraprocedural heparin, 144
- preprocedure assessment, 143
- sample handling, 144
- sinus anatomy, 136
- stimulation and sampling
 - technique, 143
- technical aspects of
 - catheterization, 139–141
- vs internal jugular venous
 - sampling, 141
- informed consent,
 - endovascular embolization of intracranial aneurysms, 10–11
- innominate artery
 - post-traumatic pseudoaneurysm/dissection, 114
 - stent placement, 112–114
 - two-wire technique, 114
- inotropic agents, 156
- intracerebral hemorrhage (ICH), post-embolization, 55–56
- intracranial aneurysms
 - characterization, 11–28
 - endovascular embolization, 10
 - aneurysm recurrence, 36–37
 - antithrombotic use, 12–13, 21
 - general anesthesia versus conscious sedation, 11–12
 - informed consent, 10–11
 - postprocedure care, 37
 - primary coil embolization, 13–19
 - thromboembolic complications, 10, 19–22
 - intraprocedural aneurysm rupture, 10, 22–24
 - general management, 22–25
 - stages, 23–24
 - peripheral aneurysms, 34–35
 - very small aneurysms, 32–33
 - wide neck aneurysm, 24–31
 - balloon remodeling technique, 25–26
 - flow diversion, 28–31
 - liquid embolic agents, 28
 - stent assisted coil embolization, 26–27
 - wide neck bifurcation aneurysms, 35
- intracranial angioplasty, 58–59
 - reported complications, 59–60
 - arterial dissection, 60–61
 - reperfusion hemorrhage, 62
 - vasospasm, 62–63
 - vessel perforation, 61–62
- intracranial pressure elevation, 157
- intraprocedural monitoring, 149–150
- iodinated contrast media, 166–172, *See also* contrast-induced nephropathy (CIN)
- ischemia, lower extremity, 6–7
- laryngeal edema, 195
- liquid embolic agents, 28, 48
- local anesthetics, 181
- lorazepam, 182, 196
- low-osmolality contrast media (LOCM), 167
- magnesium sulfate, 195
- mannitol, 195
- medication errors, 76–78
- Merci Concentric retriever, 67
 - device fracture, 74
- midazolam, 182, 196
- monitoring during
 - endovascular procedures, 149–150
- morphine, 180
- myocardial ischemia, 157
- N-acetylcysteine (NAC),
 - contrast-induced nephropathy prevention, 174
- naloxone, 181

Index

- narcotics, 154
- nephrogenic systemic fibrosis (NSF)
 - clinical manifestations, 178
 - gadolinium-based contrast agent relationship, 176–178
 - prevalence, 176
 - prevention, 178
 - risk factors, 176
 - treatment, 178
- neurocritical care
 - intraprocedural monitoring, 149–150
 - pre-procedural patient assessment, 148–149
- neurological complications, 157–159
 - brain death, 158
 - intracranial pressure elevation, 157
 - new neurological deficits, 157
 - seizures, 159
- nicardipine, 192
- norepinephrine, 198
- Onyx liquid embolic system, 28, 48
- orbital region anastomosis, 118–119
- osmotic agents, 195
- oxygenation, inadequate, 152
- patient preparation. *See* periprocedural preparation
- Penumbra Neuron MAX
 - delivery catheter, 78
- Penumbra Separator device, 68, 73
 - device fracture, 74
 - retrieval problems, 74
- percutaneous vascular closure
 - device related complications, 5–6
- peripheral arterial disease (PAD), 164–166
- periprocedural preparation, 163
 - allergy, 163–164
 - contrast-induced nephropathy (CIN), 166–178
 - peripheral arterial disease (PAD), 164–166
 - preprocedural assessment, 148–149
 - petrous-cavernous region anastomosis, 119
 - phenylephrine, 198
 - Pipeline embolization device (PED) complications, 30, *See also* flow diverters
 - pituitary gland venous drainage, 136
 - anatomic variants, 136
 - platinum coils, 48
 - polyvinyl alcohol (PVA), 48
 - popliteal artery access, 8
 - prasugrel, 190
 - premedication regimens, 164
 - pre-nidal aneurysms, 53
 - preprocedural patient assessment, 148–149
 - primary coil embolization, 13–19
 - coil misplacement or migration, 15
 - coil protrusion and distal migration, 15–17
 - coil stretching, unraveling and fracture, 17
 - coil structure, 13
 - failure of coil placement, 14
 - first coil selection, 13
 - propofol, 183, 197
 - provocative testing, 129
 - balloon test occlusion (BTO), 132–135
 - Wada test, 129–132
 - pseudoaneurysm
 - carotid, 101
 - innominate artery, 114
 - percutaneous access site, 4–5
 - pulmonary edema, 195
 - pulse oximetry, 149
 - radial artery access, 7
 - radiation
 - biological effects, 205
 - complications, 202
 - dose to patient and operator, 207
 - dose limits, 207
 - dose management, 207–209
 - exposure minimization, 210–211
 - fluoroscopy system, 205–207
 - ionizing vs non-ionizing radiation, 202
 - protection program, 204–205
 - dosimeters and protective equipment, 209–210
 - quantities and units, 204–205
 - X-ray production, 203
 - reperfusion hemorrhage, 62, 68–70
 - respiratory complications, 151–153
 - inadequate oxygenation, 152
 - inadequate ventilation, 152
 - retroperitoneal hematoma
 - groin access complications, 3–4
 - rivaroxaban, 186
 - sedation failure, 153–154
 - sedatives, 154, 196–197
 - seizures, 159
 - anticonvulsants, 182–184
 - local anesthetic reactions, 181
 - SILK flow diverter
 - complications, 30, *See also* flow diverters
 - skin necrosis, 116
 - sodium chloride, 195
 - Solitaire device, 68
 - device fracture, 74
 - spinal cord arteriovenous
 - fistula (SCAVF), 46–47
 - conus medullaris, 47
 - extradural, 46
 - intradural, 46
 - spinal cord arteriovenous malformation (SPAVM), 47–48
 - stainless steel coils, 48
 - stent placement, 58–59, *See also* carotid angioplasty and stenting (CAS); vertebral artery angioplasty and stenting
 - innominate artery, 112–114
 - reported complications, 59–60
 - difficulty in stent delivery, 63
 - in-stent stenosis, 63
 - in-stent thrombosis, 61
 - reperfusion hemorrhage, 62
 - vasospasm, 62–63
 - vessel perforation, 61–62
 - subclavian artery, 112–114

Index

- stent retriever devices, 68
- stroke
 - intra-arterial treatment
 - complications, 67–68
 - antiplatelet regimens in
 - acute stenting, 71–72
 - antithrombotics, 67
 - device fracture, 74–77
 - device stuck, 74–75
 - distal embolism, 75–76
 - futile treatment, 72
 - medication errors, 76–78
 - reperfusion hemorrhage,
 - 62, 68–70
 - risk vs benefit of
 - anticoagulant cessation,
 - 70–71
 - vessel perforation and
 - dissection, 72–76
- intracranial angioplasty and,
 - 60–61
- mechanical thrombectomy
 - benefits, 67
- technical failure in
 - intervention, 78–82
- inability to access
 - occlusion site, 78–79
- tandem stenoses/
 - occlusions, 81–82
- unsuccessful
 - thrombectomy, 79–80
- subarachnoid hemorrhage
 - (SAH), following intra-arterial stroke
 - treatment, 70
- subclavian artery stenting,
 - 112–114
- superselective testing
 - Wada testing, 130–131
 - pre-embolization
 - provocative testing, 131
- tachycardia, 194
- thrombectomy
 - devices, 67–68
 - unsuccessful, 79–80
- thromboembolic
 - complications, 159–161
- carotid angioplasty and
 - stenting, 98–101
- endovascular embolization of
 - intracranial aneurysms,
 - 10, 19–22
 - intraprocedural
 - thrombosis with coil
 - prolapse, 22
 - intraprocedural
 - thrombosis without coil
 - prolapse, 21–22
- external carotid artery
 - intervention, 125
- in-stent thrombosis, 61
- stroke intra-arterial
 - treatment, 75–76
- vertebral artery angioplasty
 - and stenting, 110
- thrombolytic agents, 191–192
- ticagrelor, 190
- transcranial Doppler (TCD),
 - 134
- Trevo device, 68
- vasopressin, 199
- vasopressors, 156, 197–199
- vasospasm, 62–63
 - external carotid artery, 118
 - vertebral artery, 111
- venous sampling, 135
- ventilation, inadequate,
 - 152
- verapamil, 192
- vertebral artery angioplasty and
 - stenting, 105–112
- bailout techniques, 109–112
 - distal embolic protection
 - device retrieval, 110
 - ensuring accurate stent
 - placement, 110
 - in-stent thrombus, 110
 - neurological status change,
 - 111
 - significant proximal
 - tortuosity, 109, 111
 - stent herniation
 - prevention, 110
 - vertebral artery dissection,
 - 110
 - vertebral artery spasm,
 - 111
- periprocedural management,
 - 108
- postprocedural management,
 - 109
- potential complications, 109
- preprocedural management,
 - 105
- vessel perforation
 - angioplasty and stent
 - placement, 61–62
 - external carotid artery
 - branches, 97
 - intra-arterial stroke
 - treatment, 72–76
- Wada test, 129–130
 - complications, 131–132
 - pre-embolization testing, 131
 - superselective testing,
 - 130–131
- warfarin, 186
- Wingspan stent system, 58–59,
 - See also* stent placement
- X-ray production, 203